SHAREHOLDER ALERT: WeissLaw LLP Investigates TGR Financial, Inc.

2021-06-03
并购
NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TGR Financial, Inc. (“TGR Financial” or the “Company”) (OTC: TGRF) in connection with the Company’s proposed acquisition by First Foundation Inc. (“First Foundation”) (NASDAQ: FFWM). Under the terms of the merger agreement, TGR Financial’s shareholders will receive 0.6068 of a share of First Foundation for each TGR Financial share they own or TGR Financial Series A non-voting convertible preferred stock, representing implied per-share merger consideration of approximately $15.24 based upon TGR Financial’s June 2, 2021 closing price of $25.12. Following consummation of the all-stock transaction, existing TGR Financial shareholders will own approximately 20.2% of the outstanding shares of First Foundation’s common stock. If you own TGR Financial shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: Or please contact:Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212) 682-3025(888) 593-4771stockinfo@weisslawllp.com WeissLaw LLP is investigating whether TGR Financial’s board acted in the best interest of TGR Financial’s public shareholders in agreeing to the proposed transaction, whether the per-share merger consideration adequately compensates TGR Financial’s shareholders, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to TGR Financial’s public shareholders. WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。